

AD _____

Award Number: DAMD17-95-1-5003

TITLE: Identification of Novel Candidate Tumor Suppressor Genes
Using *C. elegans* as a Model

PRINCIPAL INVESTIGATOR: Paul W. Sternberg, Ph.D.

CONTRACTING ORGANIZATION: California Institute of Technology
Pasadena, California 91125

REPORT DATE: November 1999

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE November 1999	3. REPORT TYPE AND DATES COVERED Final (1 Nov 94 - 31 Oct 99)	
4. TITLE AND SUBTITLE Identification of Novel Candidate Tumor Suppressor Genes Using <i>C. elegans</i> as a Model			5. FUNDING NUMBERS DAMD17-95-1-5003	
6. AUTHOR(S) Paul W. Sternberg, Ph.D.			8. PERFORMING ORGANIZATION REPORT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) California Institute of Technology Pasadena, California 91125 E-MAIL: pws@its.caltech.edu				
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words)				
<p>Molecular genetic analysis of the model organism <i>Caenorhabditis elegans</i> was used to identify and study mechanisms of action of negative regulators of tyrosine kinase/RAS mediated signal transduction that are candidate tumor suppressors. A homolog of the proto oncogene <i>cbl</i>, SLI-1, inhibits Ras activation by the epidermal growth factor receptor homolog LET-23. Three functional domains of SLI-1 have been identified. The ARK-1 protein kinase was discovered and shown to inhibit signaling by LET-23. New screens for additional negative regulators have identified at several genes that will be molecularly cloned.</p>				
14. SUBJECT TERMS Tumor Suppressor, Growth Factor Receptors, Model System, Molecular Cloning, Proto-Oncogenes, Genetic Analysis			15. NUMBER OF PAGES 7	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

___ Where copyrighted material is quoted, permission has been obtained to use such material.

___ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

___ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

X In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

N/A For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.


PI - Signature

11-30-99
Date

TABLE OF CONTENTS

	<u>Page Number</u>
FRONT COVER.....	1
REPORT DOCUMENTATION PAGE	2
FOREWORD.....	3
TABLE OF CONTENTS	4
INTRODUCTION	5
BODY	5
CONCLUSIONS.....	6

Introduction

The previous year's report was reviewed as if it were a final report, even though there was a no-cost extension. This report serves as a brief addendum to the last report.

Body

The specific goals of the project are as follows.

1. **Analyze SLI-1 function** in *C. elegans* through molecular genetics.
2. **Molecularly clone *sli-2*.**
3. **Molecularly clone *rok-1*.**
4. **Identify and clone additional genes acting in concert with *sli-1*, *sli-2*, and *rok-1***
5. **Examine the functional interactions of *sli-1*, *sli-2*, *rok-1* in regulating other conserved signaling pathways.**
6. **Clone human *sli-2*, *rok-1*, and newly identified genes from human breast tissue libraries** to generate reagents with which to test the hypothesis that these are novel tumor suppressor loci.
7. **Test the functional homology of *c-cbl* and *sli-1*** by introducing the human cDNA into transgenic nematodes defective in *sli-1*.

1. *sli-1*.

Completed.

2. *sli-2*.

Our analysis of *sli-2* is completed except for the molecular cloning. The main new genetic data is a test of the signal dependence of vulval differentiation in *sli-2* mutants. The excessive vulval differentiation displayed by *sli-2* in combination with other negative regulators is dependent on the inductive signal originating from the hermaphrodite gonad (Table1).

Table 1. *sli-2* hyperinduction is gonad dependent. Gonadal precursors were ablated in the indicated number of animals of each genotype, and the extent of vulval differentiation scored in the late L3 or L4 larval stages by examination with Nomarski optics.

	Gonad (+)	Gonad (-)
<i>sli-2</i> (<i>sy262</i>)	3.0 (n=30)	0.0 (n=6)
<i>let-23</i> (<i>sy1</i>); <i>sli-2</i> (<i>sy262</i>)	3.9 (n=31)	0.0 (n=5)
<i>sli-2</i> (<i>sy262</i>); <i>gap-1</i> (<i>n1691</i>)	3.3 (n=20)	0.0 (n=8)
<i>unc-101</i> (<i>sy108</i>); <i>sli-2</i> (<i>sy262</i>)	3.2 (n=20)	0.0 (n=6)

3. Genetics and molecular cloning of *rok-1*

Completed.

A paper on *rok-1*, renamed *ark-1* (Ack-related kinase) in response to reviewers, is being revised for the journal Cell.

4. Identification and cloning of additional negative regulators

As described in previous reports, we have identified new negative regulators of LET-23 - RAS signaling. We will continue their analysis.

The mutation 46-1 isolated as an enhancer of the multivulva phenotype of *let-23(sa62)/+* has been mapped to Linkage Group IV between *unc-24* and *dpy-20*. The map position will be refined and this locus cloned.

5. Gene interactions

Completed.

6. Human homologs

Completed. We failed to identify a human homolog of *rok-1* (*ark-1*).

7. Human *cbl* in *C. elegans*.

Completed.

Conclusions

Analysis of SLI-1, *C. elegans* homolog of Cbl, revealed functionally important domains.

Discovery of ARK-1 an Ack-related protein kinase involved in negative regulation of LET-23 signaling. Genetic analysis of ARK-1 suggests that it is recruited to the LET-23 signaling complex by the adaptor SEM-5.

New regulatory genes were discovered as suppressors or enhancers of existing mutations.

Progress by task as per original Statement of Work:

A brief description of progress on each task is listed.

Task 1A. Determine whether SLI-1 truncation decreases or increases activity of the protein as assayed in transgenic animals. •[Completed]

Task 1B. Determine role of alternative spliced form of SLI-1. •[Completed].

Task 1C. *sli-1* point mutation sequencing •[Completed].

Task 1D. *sli-1* antisera. [not completed].

Task 2A Genetic characterization of *sli-2*. [completed]

Task 2B. Molecular cloning of SLI-2 from *C. elegans*. [not completed]

Task 3. Genetics and molecular cloning of ROK-1 from *C. elegans*.
[Completed]

Task 4. Identification by genetic screens of new loci.

- a. **Screen for new mutations, carry out screens in parallel.** [completed]
- b. **Genetic mapping and complementation of new mutations, parallel experiments** •[completed]
- c. **Molecular cloning** [not completed]

Task 5. Examination interactions of genes in vivo •[completed]

Task 6. Human homologs. •[unsuccessful]

Task 7. Introduction of *c-cbl* cDNA into transgenic nematodes. a. **Construct *sli-1/c-cbl* hybrid genes** b. **Examine phenotypes of transgenic animals.** • [completed].